Compare Aptiv PLC (APTV) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aptiv PLC vs TG Therapeutics Inc — how do they compare? Aptiv PLC trades at $48.51 (market cap $10.30B), while TG Therapeutics Inc trades at $49.62 (market cap $7.64B). The key difference: Aptiv PLC is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Aptiv PLC nearer its low. Which is the better fit depends on your goals.
| APTV | TGTX | |
|---|---|---|
Market Cap | $10.30B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $59.06 |
52-Week Low | $46.30 | $26.94 |
Enterprise Value | $15.23B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APTV trades at $48.26, down 3.11% amid bearish technical signals and lowered 2026 guidance. Despite beating Q2 earnings estimates with $1.63 EPS versus $1.42 expected, the company faces China demand weakness and program delays. Valuation metrics appear attractive with P/E of 22.45 and P/S of 0.52, while analyst consensus remains strongly bullish with 63.6% buy ratings and $70.09 price target.
Near-term execution risks and cash flow pressures create uncertainty, but the stock's discounted valuation and consistent earnings beats offer potential upside for patient investors. The key challenge remains navigating China market softness and delayed program launches while maintaining margin improvements.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
